Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Halts REGN475 Study

By Drug Discovery Trends Editor | January 3, 2011

NEW YORK (AP) – The Food and Drug Administration placed studies of Regeneron Pharmaceuticals Inc. and Sanofi-Aventis’ potential osteoarthritis drug on hold because of potential harm to patients’ bones.

In a Securities and Exchange Commission filing on Monday, Regeneron said the Food and Drug Administration place studies of REGN475 on hold after a patient being treated with the same class of drug in another company’s study developed avascular necrosis of a joint.

Avascular necrosis, sometimes referred to as bone death, involves the cutoff of blood to the bone, causing the bone tissue to die and the eventual collapse of the bone.

REGN475, also called SAR164877, is a nerve growth factor inhibitor, which aims to block pain.

The FDA is concerned the side effect could be an issue with all drugs in the same class.

The company said there are currently no ongoing studies of REGN475.

In July, at the FDA’s request, Pfizer Inc. stopped testing its potential nerve growth factor inhibitor tanezumab for patients with chronic low back pain, nerve damage from diabetes and arthritis.

Date: December 27, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50